Innovation

The research work carried out by the CRCL teams can be at the origin of projects with high application potential which sometimes materialize with the creation of start-ups. Presentations.

Founded in October 2019 by Prof. Stéphane Depil, MD, PhD, onco-hematologist at CLB, based on the research work from his academic lab, ErVaccine Technologies is a spin off from Centre Léon Bérard (CLB) / Cancer Research Center of Lyon (CRCL).

Currently at a preclinical stage of development, the company specializes in the development of next generation cancer vaccines, and cell therapies based on modified T lymphocytes, targeting new families of non-conventional tumor antigens such as those derived from endogenous retroviruses (identified and patented therapeutic targets).

Know more

StromaCare was structured around the research group “Stromal Immune Interactions in Cancer” (Dir A. Hennino) bringing together players in basic research from Cancer Research Center of Lyon and clinicians from the Centre Léon Bérard (Lyon Anti-Cancer Center – CLB).

StromaCare is dedicated to the development of innovative oncology drugs, based on modulation of stromal components, for the treatment of solid tumors. StromaCare will focus on the development of these innovative compounds from translational research to proof of concept in humans, which represents its specific know-how and area of expertise.

Know more

Resulting from the work of Patrick Mehlen’s research team, Netris Pharma’s vision is to make a significant contribution to the development of innovative therapeutic molecules for treating cancer by targeting Dependence Receptors.

Discover Netris Pharma

Resulting from the work of Charles Dumontet’s research team, Hephaistos Pharma is preclinical stage Biotech company developing the next generation of oncology treatments that will be boost immune system to treat incurable cancers.

Discover Hephaistos Pharma

Resulting from the work of Toufic Renno’s research team, Tollys was built on the discovery that the activation of the TLR3 receptor leads to differential effects in cancer cells and normal and immune cells. Tollys used these unique properties to rationally design a family of TLR3 agonists, of which TL-532 is the lead-candidate.

Discover Tollys